Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart William D. Travis, MD, Elisabeth Brambilla,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Ugonna N. Ihekweazu, BS, William D. Travis, MD, Raja M. Flores, MD

The 2015 World Health Organization Classification of Lung Tumors

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Interpretation of Anti-ALK Immunohistochemistry Results

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart William D. Travis, MD, Elisabeth Brambilla,

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities Matthew P. Humphries, PhD, Stephen.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study Erik Thunnissen, MD, PhD, Masayuki.

“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy Kentaro Ito, MD, Osamu Hataji, MD, Koji Katsuta, MD, Tetsu Kobayashi,

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Diagnostic Mutation Profiling and Validation of Non–Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform Anne Marie Quinn, FRCPath,

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer Antonio Calles, MD, Xiaoyun Liao, MD,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

In This Issue Journal of Thoracic Oncology

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Mitotic Inhibitors Journal of Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib Sanjay Popat, MRCP, PhD, Alexandra Vieira de.

Phase I Study of Lenalidomide in Solid Tumors

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

In This Issue Journal of Thoracic Oncology

Genetic Changes in Squamous Cell Lung Cancer: A Review

Ethnic Differences in the Management of Lung Cancer in New Zealand

Transcutaneous Computed Bioconductance Measurement in Lung Cancer: A Treatment Enabling Technology Useful for Adjunctive Risk Stratification in the Evaluation.

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

IASLC 6th Latin American Conference on Lung Cancer

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Who should decide margin length in pulmonary excision of lung cancer?

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

The IASLC Lung Cancer Staging Project

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G. Nicholson, DM, FRCPath, Yasushi Yatabe, MD, PhD, Ignacio I. Wistuba, MD, PhD, Fred R. Hirsch, MD, PhD Journal of Thoracic Oncology Volume 10, Issue 7, Pages 985-989 (July 2015) DOI: 10.1097/JTO.0000000000000526 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Programmed death receptor-1 with its ligand (PDL-1) immunostaining performed using the E1LN3N clone anti-PD-L1 from Cell Signaling Technology (Boston) with standard detection techniques. A, Squamous cell carcinoma showing a strong, uniform positive reaction in tumor cells. B, Despite being negative in tumor cells in the center of the image, there is a positive reaction in macrophages and other immune cells in the tumor stroma. C, Most alveolar macrophages are positive for PD-L1. D, This adenocarcinoma is negative for PD-L1. It should be noted that this immunohistochemistry clone was not used for PD-L1 detection in any of the trials discussed in this review. Journal of Thoracic Oncology 2015 10, 985-989DOI: (10.1097/JTO.0000000000000526) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions